Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI069501-14S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $601,237
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    CASE WESTERN RESERVE UNIVERSITY
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Other

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The primary objective of this supplemental application is to rapidly enhance the ability of the twodomestic CRSs in the Case Clinical Trials Unit to enroll and follow participants in COVID-19 preventionand treatment trials, with a particular emphasis on enhancing the sites' capacity to collect, process,store, and ship longitudinal biological specimens from these participants at any stage of the diseaseprocess. The following specific aims are proposed to accomplish this objective:Specific aim 1: To expand CRS capacity to identify new SARS-CoV-2 infections and to offer participationin clinical trials and observational studies. A key element to contribute meaningfully to prevention andtreatment trials will be to have access to recently diagnosed persons with SARS-CoV-2 infection who canbe offered participation. Here, we will enhance the capacity of the two CRSs to access these potentialparticipants by establishing partnerships with central laboratory leadership and expanding support forresearch staff who can support expanded testing and offer participation in research early after diagnosis.Specific aim 2: To improve CRS infrastructure to facilitate specimen collection and longitudinal follow-up of SARS-CoV-2 infected study participants. Among the challenges to refashion the CRSs to conductCOVID-19 trials are limitations in access to secure facilities and personal protection equipment. To addressthis, dedicated protective enclosures will be established at the Case CRS, and dedicated PPE will beacquired where needed for the duration of this funding period, which will be the critical interval duringwhich supply bottlenecks are anticipated to persist.Specific aim 3: To enhance participation of at-risk and SARS-CoV-2-infected persons in clinical researchprotocols. Recruitment of at-risk and infected participants into COVID-19 trials will require novelstrategies to reach out into the community, and to engage potential participants into clinical researchdespite no existing connection to the CRSs. To overcome these obstacles, we will devote dedicated effortfrom outreach coordinators specifically to COVID-19 recruitment, and establish online advertisementcampaigns to maximize opportunities for enrollment.Specific aim 4: To increase CRS capacity for processing and storage of biological specimens from COVID-19 research participants. The final barrier to processing, storing, and archiving specimens from COVID-19prevention and treatment clinical trials is the need for enhanced biosafety precautions in the processinglaboratory. At both CRSs, enhanced BSL-2 workstations will be established, with dedicated equipmentwhen needed, to increase the ability to process efficiently specimens derived from COVID-19 trials.